A study of several hematological and immunological parameters of patients with rheumatoid arthritis and their relationship with type 2 diabetes mellitus
DOI:
https://doi.org/10.15584/ejcem.2025.2.9Keywords:
interleukin, rheumatoid arthritis, type 2 diabetes mellitusAbstract
Introduction and aim. Rheumatoid arthritis (RA) is a systemic inflammation that damages the joints and causes disability. In RA, glucocorticoids reduce inflammation and peripheral insulin resistance. This study aimed to investigate hematological and immunological parameters, including interleukin-24 (IL-24), interleukin-32 (IL-32), and rheumatoid factor (RF), in patients with RA, type 2 diabetes mellitus, or both, and to assess their interrelationships.
Material and methods. A case-control study on RA and type 2 diabetes mellitus was conducted at Al-Nasiriyah Education Hospital with 100 blood samples collected from patients, divided into four groups. Complete blood counts (CBC), erythrocyte sedimentation rate (ESR), RF, IL-24, and IL-32 levels were measured using automated analyzers and enzyme-linked immunosorbent assay.
Results. Patients with both diseases showed elevated ESR (p<0.001) and RF (p<0.01). RA patients increased significantly in ESR and RF, but there was no statistically significant difference in RF in type 2 diabetic patients. IL-24 was not statistically significantly increased in RA patients. IL-32 levels increased significantly in type 2 diabetes (p=0.02), while RA showed no significant difference.
Conclusion. Patients with RA have elevated levels of IL-32 expression and has a positive correlation with indicators of RA activity indicators such as ESR and RF. An increase in IL-24 and IL-32 in RA patients indicates a positive correlation between IL-24 and IL-32. Diabetic patients exhibit significantly elevated pro-inflammatory properties of IL-32.
Downloads
References
Kim JW, Suh CH. Systemic Manifestations and Complications in Patients with Rheumatoid Arthritis. J Clin Med. 2020;9(6):2008. doi: 10.3390/jcm9062008
Jabbar SH. Association of genetic variation in tumor necrosis factor: gene with susceptibility to rheumatoid arthritis in southern Iraq. Univ Thi-Qar J Sci. 2023;10(1):194-200.
van den Oever IAM, Baniaamam M, Simsek S, et al. The effect of anti-TNF treatment on body composition and insulin resistance in patients with rheumatoid arthritis. Rheumatol Int. 2021;41(2):319-328. doi: 10.1007/s00296-020-04666-6
Tian Z, Mclaughlin J, Verma A, Chinoy H, Heald AH. The relationship between rheumatoid arthritis and diabetes mellitus: a systematic review and meta-analysis. Cardio Endo & Metabolism. 2021;10(2):125-131. doi: 10.1097/xce.0000000000000244
Al-seidi FA. The incidence of proteinuria among diabetic patients in relation to the level of glycated Hb, duration of the disease& types of treatment in Thi-Qar province. J THI-QAR Sci. 2016;5(4).
de Oliveira PG, Farinon M, Sanchez-Lopez E, Miyamoto S, Guma M. Fibroblast-Like Synoviocytes Glucose Metabolism as a Therapeutic Target in Rheumatoid Arthritis. Frontiers in Immunology. 2019;10. doi: 10.3389/fimmu. 2019.01743
McInnes IB, Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis. The Lancet. 2017;389 (10086):2328-2337. doi: 10.1016/s0140-6736(17) 31472-1
Sung WY, Tsai WC. Rethink about the role of rheumatoid factor and anti-citrullinated protein antibody in rheumatoid arthritis. Rheumatol and Immun R. 2021;2(1):19-25. doi: 10.2478/rir-2021-0003
Carubbi F, Alunno A, Gerli R, Giacomelli R. Post-Translational Modifications of Proteins: Novel Insights in the Autoimmune Response in Rheumatoid Arthritis. Cells. 2019;8(7):657. doi: 10.3390/cells8070657
Hassanzadeh S, Gholamnezhad M. Investigating the importance and causes of rheumatoid arthritis and its effective treatments: a review study. Revista Latinoamericana de Hipertensión. 2020;15(1):59-63.
Fawzy RM, Said EA, Mansour AI. Association of neutrophil to lymphocyte ratio with disease activity indices and musculoskeletal ultrasound findings in recent onset rheumatoid arthritis patients. The Egyptian Rheumatologist. 2017;39(4):203-206. doi: 10.1016/j.ejr.2017.05.001
Tekeoğlu İ, Gürol G, Harman H, Karakeçe E, Çiftçi İH. Overlooked hematological markers of disease activity in rheumatoid arthritis. Inter J of Rheumatic Diseases. 2016;19(11):1078-1082. doi: 10.1111/1756-185x.12805
Shapiro SC. Biomarkers in Rheumatoid Arthritis. Cureus. Published online, 2021. doi:10.7759/cureus.15063
Chen J, Caspi RR, Chong WP. IL-20 receptor cytokines in autoimmune diseases. J of Leuko Biology. 2018;104(5):953-959. doi: 10.1002/jlb.mr1117-471r
Wai Chin Chong, Mattapallil MJ, Kumarkrishna Raychaudhuri, et al. The Cytokine IL-17A Limits Th17 Pathogenicity via a Negative Feedback Loop Driven by Autocrine Induction of IL-24. 2020;53(2):384-397.e5. Doi: 1016/j.immuni.2020.06.022
Jan Hendrik Niess, Petr Hrúz, Tanay Kaymak. The Interleukin-20 Cytokines in Intestinal Diseases. Frontiers in Immunology. 2018;9. doi: 10.3389/fimmu.2018.01373
Persaud L, De Jesus D, Brannigan O, et al. Mechanism of Action and Applications of Interleukin 24 in Immunotherapy. Int J Mol Sci. 2016;17(6):1-13. doi: 10.3390/ijms17060869
Zhong Y, Zhang X, Chong W. Interleukin-24 Immunobiology and Its Roles in Inflammatory Diseases. Int J Mol Sci. 2022;23(2):627. doi: 10.3390/ijms23020627
Kim S-H, Han S-Y, Azam T, Yoon D-Y, Dinarello CA. Interleukin-32: a cytokine and inducer of TNFα. Immunity. 2005;22(1):131-142. doi: 10.1016/j.immuni.2004.12.003
Kobayashi H, Lin PC. Molecular characterization of IL-32 in human endothelial cells. Cytokine. 2009;46(3):351-358. doi: 10.1016/j.cyto.2009.03.007
Khawar MB, Abbasi MH, Sheikh N. IL-32: A Novel Pluripotent Inflammatory Interleukin, towards Gastric Inflammation, Gastric Cancer, and Chronic Rhino Sinusitis. Mediators of Inflammation. 2016;2016:1-8. doi: 10.1155/2016/8413768
Zamani B, Maedeh Najafizadeh, Hossein Motedayyen, Reza Arefnezhad. Predicting roles of IL-27 and IL-32 in determining the severity and outcome of COVID-19. Int J Immunopath Pharma. 2022;36:1-10. doi: 10.1177/03946320221145827
Damen MSMA, Schraa K, Tweehuysen L, et al. Genetic variant in IL-32 is associated with the ex vivo cytokine production of anti-TNF treated PBMCs from rheumatoid arthritis patients. Sci Rep. 2018;8(1):1-8. doi: 10.1038/s41598-018-32485-0
Walle M, Alemayehu E, Tesfaye A, et al. Comparison of erythrocyte sedimentation rate measurement between Westergren method and automated method among patients attending Jigjiga University Sheik Hassen Yabare Referral Hospital, Jigjiga, Ethiopia. Front Med. 2024;11. doi: 10.3389/fmed.2024.1414097
Korkmaz G, Özmen M, Can G, Tarhan E. The Relationship of Neutrophil Lymphocyte Ratio With Prognosis And Disease Activity In Patients With Rheumatoid Arthritis. CMJ. Aralık. 2022;44(4):430-435. doi: 10.7197/cmj.1175878
KC SR, Shrestha S, KC G, Gyawali P, Dahal S, Maharjan B. Complete Blood Count Parameters in Arthritis. Nepal M C J. 2020;22(3):99-105. doi: 10.3126/nmcj.v22i3.32621
McInnes IB, Schett G. The Pathogenesis of Rheumatoid Arthritis. New England J of M. 2011;365(23):2205-2219. doi: 10.1056/nejmra1004965
Badawy ER, Gamal NM, Gheita A. Emerging Value of Platelet-to-Hemoglobin Ratio and Monocyte-to-Hemoglobin Ratio in Assessment of Rheumatoid Arthritis Patients. The M J of Cairo University. 2021;89(9):1991-1999. doi: 10.21608/mjcu.2021.203333
Larasati RA, Harbuwono DS, Rahajeng E, et al. The Role of Butyrate on Monocyte Migration and Inflammation Response in Patient with Type 2 Diabetes Mellitus. Biomedicines. 2019;7(4):74. doi: 10.3390/biomedicines7040074
Mathsson L, Lampa J, Mullazehi M, Rönnelid J. Immune complexes from rheumatoid arthritis synovial fluid induce FcγRIIa dependent and rheumatoid factor correlated production of tumour necrosis factor-α by peripheral blood mononuclear cells. Arthritis Research & Therapy. 2006;8(3):1-10. doi: 10.1186/ar1926
Manning JE, Lewis JW, Marsh LJ, McGettrick HM. Insights Into Leukocyte Trafficking in Inflammatory Arthritis – Imaging the Joint. Front Cell Develop Biol. 2021;9:110. doi: 10.3389/fcell.2021.635102
Fu H, Qin B, Hu Z, et.al Neutrophil-and platelet-to-lymphocyte ratios are correlated with disease activity in rheumatoid arthritis. Clin Lab. 2015;61(3-4):269-273. doi: 10.7754/Clin.Lab.2014.140927
Shimamoto K, Ito T, Ozaki Y, et al. Serum interleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritis. The J of Rheumatol. 2013;40(7):1074-1081. doi: 10.3899/jrheum.121389
Hashizume M, Higuchi Y, Uchiyama Y, Mihara M. IL-6 plays an essential role in neutrophilia under inflammation. Cytokine. 2011;54(1):92-99. doi: 10.1016/j.cyto.2011.01.007
Harifi G, Sibilia J. Pathogenic role of platelets in rheumatoid arthritis and systemic autoimmune diseases. Saudi M J. 2016;37(4):354-360. doi: 10.15537/smj.2016.4.14768
Chen Y, Xu S, Xu Y, et al. Inflammatory anemia may be an indicator for predicting disease activity and structural damage in Chinese patients with rheumatoid arthritis. Clin Rheumatol. 2020;39(6):1737-1745. doi: 10.1007/s10067-019-04873-y
Helal RM, El-Naggar MH, Zahar MK, Abo El-Nasr NM. Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio as Marker of Disease Activity in Rheumatoid Arthritis. The M J of Cairo University. 2019;87:139-145. doi: 10.21608/mjcu.2019.52333
Ganna S. The relationship between hemoglobin level and disease activity in patients with rheumatoid arthritis. Revista Brasileira de Reumatologia (English Edition). 2014;54(6):437-440. doi: 10.1016/j.rbre.2014.06.003
Khadim RM, Al-Fartusie FS. Evaluation of Liver Function and Lipid profiles in Iraqi patients with Rheumatoid Arthritis. J of Physics: Conference Series. 2021;1853(1):1-12. doi: 10.1088/1742-6596/1853/1/012040
Crowson CS, Rahman MU, Matteson EL. Which Measure of Inflammation to Use? A Comparison of Erythrocyte Sedimentation Rate and C-Reactive Protein Measurements from Randomized Clinical Trials of Golimumab in Rheumatoid Arthritis. J Rheumatol. 2009;36(8):1606-1610. doi: 10.3899/jrheum.081188
Al-Nimer MSM, Ratha R. The Erythrocyte Sedimentation Rate is a Simple, Sensitive and Predictive Hematological Index for Non-Septic Diabetic Foot Syndrome: A Cross-Sectional Study. Clinical Diabetology. 2022;11(6):372-378. doi: 10.5603/DK.a2022.0052
Olumuyiwa-Akeredolu OO, Pretorius E. Platelet and red blood cell interactions and their role in rheumatoid arthritis. Rheumatology International. 2015;35(12):1955-1964. doi: 10.1007/s00296-015-3300-7
Youssef A, Elshabacy F, Abdelrahman S, Mohamed T. Comparison between ESR and C-Reactive Protein(CRP) as a Marker of Disease activity in Patients with Rheumatoid Arthritis. Egyptian J of Rheumatol and Clin Immuno. 2015;3(1):77-81. doi: 10.21608/ejrci.2015.9319
Kragstrup TW, Otkjaer K, Holm C, et al. The expression of IL-20 and IL-24 and their shared receptors are increased in rheumatoid arthritis and spondyloarthropathy. Cytokine. 2008;41(1):16-23. doi: 10.1016/j.cyto.2007.10.004
Tue Wenzel Kragstrup, Greisen S, Morten Aagaard Nielsen, et al. The interleukin-20 receptor axis in early rheumatoid arthritis: novel links between disease-associated autoantibodies and radiographic progression. Arthritis Research & Therapy. 2016;18(1). doi: 10.1186/s13075-016-0964-7
Kohem CL, Brezinschek RI, Wisbey H, Tortorella C, Lipsky PE, Oppenheimer-Marks N. Enrichment of differentiated CD45RBdim, CD27 – memory T cells in the peripheral blood, synovial fluid, and synovial tissue of patients with rheumatoid arthritis. Arthritis & Rheumatism. 1996;39(5):844-854. doi: 10.1002/art.1780390518
Aya Refat E, Zainab Hussein AH. Il-24 and il-29 in t2dm with and without diabetic foot ulcers. acta chemica iasi. 2022;30(2):103-119. doi: 10.47743/achi-2022-2-0005
Tamai H, Miyake K, Yamaguchi H, et al. AAV8 vector expressing IL24 efficiently suppresses tumor growth mediated by specific mechanisms in MLL/AF4-positive ALL model mice. Blood. 2012;119(1):64-71. doi: 10.1182/blood-2011-05-354050
Seegobin SD, Ma MH, Dahanayake C, et al. ACPA-positive and ACPA-negative rheumatoid arthritis differ in their requirements for combination DMARDs and corticosteroids: secondary analysis of a randomized controlled trial. Arthritis Research & Therapy. 2014;16(1):R13. Doi: 10.1186/ar4439
Hassan SB, Abdullah HN, Zakair KY. The role of IL-24 as a pro-inflammatory cytokine in some Iraqi rheumatoid arthritis patients. J Pakistan Med Ass. 2023;73(9):98-101. doi: 10.47391/jpma.iq-21
Mohammed Jasim E, Khudhur Jameel S, Ihsan Awadh N. Estimation of Interleukin 32 and Interleukin 37 Serum Levels in Iraqi Patients with Rheumatoid Arthritis. Arch Razi Inst. 2023;78(2):743-750. doi: 10.22092/ARI.2022.359861.2489
Gui M, Zhang H, Zhong K, Li Y, Sun J, Wang L. Clinical Significance of Interleukin-32 Expression in Patients with Rheumatoid Arthritis. Asian Pac J Allergy Immunol. 2013;31(1):73-78.
Dinarello CA. Blocking IL-1 in systemic inflammation. J Exper M. 2005;201(9):1355-1359. doi: 10.1084/jem.20050640
Abid SM, Alaaraji SF, Alrawi KF. Study of Interleukins 13, 18, 27, 32 and 38 Levels in Iraqi Type 2 diabetes with Insulin Resistance. J Educ Sci Stud. 2019;14(4):1-14.
Al-Taee MM, Mohmood DI, Muhammed MM. Determining levels of rheumatoid factor (RF) and C-reactive protein (CRP) in a blood sample of Iraqi patients with rheumatoid arthritis (RA). Al-Nisour J Med Sci. 2019;1(1):133-139.
Hassoon HJ, Jasim WE, Abbas AA. The Evaluation of some biomarkers according to rheumatoid factor in early diagnosis of rheumatoid arthritis from Iraqi patients. Iraqi J Sci. 2020;61(9):2196-2203. doi: 10.24996/ijs.2020.61.9.6
Eisen HN. Affinity Enhancement of Antibodies: How Low-Affinity Antibodies Produced Early in Immune Responses Are Followed by High-Affinity Antibodies Later and in Memory B-Cell Responses. Cancer Immunology Research. 2014;2(5):381-392. doi: 10.1158/2326-6066.cir14-0029
Mohammad HA, Abeer JH, Enas JH. Risk factors and early detection of diabetes mellitus in early rheumatoid arthritis women. J Faculty Med Baghdad. 2018;60(1):74-76.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 European Journal of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
